Clinical trials: ORR
ORR,OS,PFS
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Evaluation of Efficacy and Safety of Sintilimab Plus Bevacizumab and AG Regimen as First-Line Therapy in Patients with Surgically Ineligible Locally Advanced or Metastatic Cholangiocarcinoma Objectives: Primary Objective: To…
- Trial name
- NCT07328802
- Testing
- Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory…
- Trial name
- NCT03707847
- Testing
- Crizotinib, Etoposide Capsule, Auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Neuroendocrine Carcinoma
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. SOX regimen has shown promising in previous study.
- Trial name
- NCT03279614
- Testing
- SOX
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University
Gastric Cancer
Study of S-1 Plus LV for Advanced Gastric Cancer
The purpose of this study is to evaluate the effectiveness and safety of S-1 plus Leucovorin (1 week on and 1 week off) as first-line treatment for patients with metastatic and recurrent gastric cancer.
- Trial name
- NCT02090153
- Testing
- S-1, LV
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine…
- Trial name
- NCT03422029
- Testing
- 177Lu-Dotatate PRRT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06949033
- Testing
- Neoadjuvant cadonilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 668 people
- Sponsor
- Zuoyi Jiao
Primary Central Nervous System Lymphoma
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT04831658
- Testing
- the dose-escalation phase
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Mingzhi Zhang
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer…
- Conditions
- Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- DOORwaY90 (NCT04736121)
- Testing
- Resin microspheres containing yttrium-90 (Y-90)
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sirtex Medical
Relapsed and Refractory, Diffuse Large B Cell Lymphoma
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.
- Trial name
- NCT03376958
- Testing
- Apatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Zhengzhou University
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Leukemia
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
- Trial name
- NCT01893372
- Testing
- Eltrombopag, Hypomethylating Agent (HMA)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
ORR, PFS
A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
Given the rarity of nasal and paranasal sinus rhabdomyosarcoma (SNRMS), there is a lack of literature on systemic treatment models for adult SNRMS, let alone prospective clinical studies.
- Conditions
- ORR, PFS, OS
- Trial name
- NCT07449949
- Testing
- VMAT
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to compare the efficacy and safety of neoadjuvant apatinib combined with sintilimab and perioperative SOX chemotherapy versus neoadjuvant sintilimab combined with perioperative SOX chemotherapy in locally advanced…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06925243
- Testing
- Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 682 people
- Sponsor
- Zuoyi Jiao
Urothelial Bladder Cancer, Triple-negative Breast Cancer
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
- Conditions
- Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02527434
- Testing
- Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
ORR, OS
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
In the past 10 years, there have been many effective explorations on the treatment of NK/TCL at home and abroad, which has innovated the treatment mode.
- Conditions
- ORR, OS, PFS
- Trial name
- NCT07450040
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Aplastic Anemia
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia.
- Trial name
- NCT05399732
- Testing
- Luspatercept, Cyclosporine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Bing Han